| 0 (0%) | 11-11 19:23 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 7.47 | 1-year : | 8.73 |
| Resists | First : | 6.4 | Second : | 7.47 |
| Pivot price | 6.15  |
|||
| Supports | First : | 4.84  |
Second : | 3.89 |
| MAs | MA(5) : | 6.11 |
MA(20) : | 5.98 |
| MA(100) : | 4.49 |
MA(250) : | 5.16 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 46.6 |
D(3) : | 47.7 |
| RSI | RSI(14): 71.1 |
|||
| 52-week | High : | 7.65 | Low : | 3.52 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ KZR ] has closed below upper band by 38.5%. Bollinger Bands are 74% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 6.24 - 6.27 | 6.27 - 6.3 |
| Low: | 6.02 - 6.05 | 6.05 - 6.09 |
| Close: | 6.11 - 6.17 | 6.17 - 6.23 |
Fri, 07 Nov 2025
Kezar Life Sciences Announces Major Workforce Reduction - MSN
Fri, 07 Nov 2025
Kezar Life Sciences Inc expected to post a loss of $2.08 a share - Earnings Preview - TradingView
Fri, 07 Nov 2025
Kezar (NASDAQ: KZR) posts 36% remission in AIH at steroid doses ≤5 mg/day at AASLD - Stock Titan
Sat, 18 Oct 2025
William Blair downgrades Kezar Life Sciences (KZR) to a Hold - The Globe and Mail
Fri, 17 Oct 2025
Kezar Life Sciences Stock Hit With Downgrades And Price Target Cuts: Retail Keeps Hopes Alive - Stocktwits
Fri, 17 Oct 2025
Kezar Launches Review After FDA Blocks Liver Drug Plans - Kezar Life Sciences (NASDAQ:KZR) - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 7 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 10.5 (%) |
| Held by Institutions | 63.9 (%) |
| Shares Short | 764 (K) |
| Shares Short P.Month | 762 (K) |
| EPS | -9.7 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 12.55 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -32.8 % |
| Return on Equity (ttm) | -58.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -7.39 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -10.22 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -64 (M) |
| Levered Free Cash Flow | -42 (M) |
| PE Ratio | -0.64 |
| PEG Ratio | 0 |
| Price to Book value | 0.49 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.71 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|